沙库巴曲缬沙坦钠治疗维持性血液透析合并心力衰竭患者的效果

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (599 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect and adverse reactions of Sacubitril Valsartan Sodium in the treatment of patients with maintenance hemodialysis (MHD) combined with heart failure.Methods A total of 44 patients with MHD and heart failure who hospitalized in the Department of Nephrotic Rheumatism of the Central Hospital of Qianjiang from October 2017 to June 2019 were selected as the research subjects.They were divided into observation group and control group according to the random number table method,with 22 patients in each group.All patients received MHD and symptomatic support therapy,the observation group was treated with Sacubitril Valsartan Sodium on this basis.The total effective rate and the total incidence of adverse reactions during the treatment of two groups were compared,at the same time,the cardiac function indexes such as left ventricular end systolic diameter (LVESD),left ventricular end diastolic diameter (LVEDD),stroke volume (SV),left ventricular ejection fraction (LVEF) and the expression levels of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP),angiotensin Ⅱ(Ang Ⅱ),aldosterone(ALD) in the two groups before and after treatment were detected.Results The total effective rate of observation group was higher than that of control group,and the difference was statistically significant (P＜0.05).There were no significant differences in cardiac function indexes between two groups before treatment (P＞0.05).After treatment,the LVEF and SV of two groups were higher than those of before treatment,the LVESD and LVEDD of two groups were lower than those before treatment,the LVEF and SV in observation group were higher than those of control group,and the LVESD and LVEDD in observation group were lower than those of control group,the differences were statistically significant(P＜0.05).There were no significant differences in the expression levels of cytokines between the two groups before treatment (P＞0.05).After treatment,the expression levels of cytokines such as NT-proBNP,Ang Ⅱ,ALD were lower than those of before treatment,and the indexes of observation group were lower than those of the control group,the differences were statistically significant (P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05).Conclusion The efficacy of Sacubitril Valsartan Sodium in the treatment of MHD patients with heart failure is significant,which can not only effectively inhibit ventricular remodeling,but also significantly improve the neuroendocrine status,and has a high safety and reliability.

Key words： Sacubitril Valsartan Sodium Maintenance hemodialysis Heart failure Effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I22/10

[1]	曹有文，陈红.长期维持性血液透析患者并发心力衰竭的影响因素分析[J].临床合理用药，2020，13（3）：10-12.
[2]	李俊，王剑松，张之甲.维持性血液透析患者微炎症状态与心血管并发症相关性研究[J].昆明医学院学报，2011，32（1）：51-54.
[3]	程小兵.沙库巴曲缬沙坦治疗心力衰竭的作用机制、临床应用及指南推荐意见[J].实用心脑肺血管病杂志，2019，27（9）：1-4.
[4]	中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华实用乡村医生杂志，2014，42（2）：3-10.
[5]	刘焰华，李枫，汪蛟龙，等.沙库巴曲缬沙坦治疗慢性心力衰竭[J].长春中医药大学学报，2019，35（3）：457-460.
[6]	Choonq Hou K，Sin Yoong Konq K，Kee Yi Shern T，et al.Impact of chronic kidney insufficiency on cardiovascular outcomes in patients that undergo coronary revascularization：a historical review[J].ASEAN Heart J，2016，24（1）：8.
[7]	付志辉.终末期肾病合并心力衰竭患者维持性血液透析微炎症状态与营养状况、心功能的相关性[J].中国当代医药，2021，28（8）：55-58.
[8]	Beusekamp JC，Tromp J，vander Wal HH，et al.Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF[J].Eur J Heart Fail，2018，20（5）：923-930.
[9]	Correction to：2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure：A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J].Circulation，2016，134（13）：e298-293.
[10]	Wang TD，Tan RS，Lee HY，et al.Effects of Sacubitril/Valsartan （LCZ696） on Natriuresis，Diuresis，Blood Pressures，and NT-proBNP in Salt-Sensitive Hypertension[J].Hypertension，2017，69（1）：32-41.
[11]	Albert NM，Swindle JP，Buysman EK，et al.Lower hospitalization and healthcare costs with sacubitril/valsartan versus Angiotensin-Converting enzyme inhibitor or Angiotensin-Receptor blocker in a retrospective analysis of patients with heart failure[J].J Am Heart Assoc，2019，8（9）：11089.
[12]	Cunningham JW，Claggett BL，O′Meara E，et al.Effect of Sacubitril/Valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF[J].J Am Coll Cardiol，2020，76（5）：503-514.
[13]	Myhre PL，Vaduganathan M，Claggett B，et al.B-type natriuretic peptide during treatment with Sacubitril/Valsartan：the PARADIGM-HF trial[J].J Am Coll Cardiol，2019，73（11）：1264-1272.
[14]	魏子寒，李栋博，元峥，等.沙库巴曲缬沙坦治疗左心疾病相关性肺动脉高压的临床研究[J].中国临床药理学与治疗学，2019，24（1）：57-62.
[15]	普顺华，关英霞，杨志刚，等.沙库巴曲缬沙坦治疗左心室射血分数降低心力衰竭患者的临床疗效观察[J].中国心血管病研究，2019，17（3）：266-269.
[16]	高扬，栾波，高尧，等.沙库巴曲/缬沙坦治疗慢性心力衰竭的临床观察[J].中国循证心血管医学杂志，2019，11（5）：595-597.
[17]	杨红，孙晓妍，刘静，等.沙库巴曲缬沙坦对老年人急性心肌梗死后慢性心力衰竭发生的影响[J].中华老年医学杂志，2020，39（1）：38-42．
[18]	陈宝珍，罗建.重组人脑利钠肽联合沙库巴曲缬沙坦钠治疗扩张型心肌病合并心力衰竭的疗效观察[J].中国医药科学，2021，11（24）：22-25，88.
[19]	李文波.沙库巴曲缬沙坦钠治疗慢性心力衰竭的效果[J].中国当代医药，2020，27（3）：91-93.
[20]	田得宽，苏晓灵，李卫，等.沙库巴曲缬沙坦钠对青海地区射血分数降低的心力衰竭患者心功能及心肌纤维化指标的疗效评价[J].临床心血管病杂志，2022，38（2）：137-141.
[21]	孙洁，陈欣.沙库巴曲缬沙坦对不同病程的慢性心力衰竭患者的疗效评价[J].临床心血管病杂志，2021，37（10）：942-946.
[22]	靳海斌.慢性心力衰竭的神经调节治疗及沙库巴曲缬沙坦钠应用新进展[J].心血管病学进展，2019，40（2）：283-286.